MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.09 CHF | +4.82% |
|
-6.60% | +77.03% |
| Jun. 20 | Top Premarket Gainers | MT |
| Jun. 17 | Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 377.3 | 604.8 | 575.4 | 200.5 | 113 | 192.8 | - | - |
| Enterprise Value (EV) 1 | 283.5 | 431.1 | 442.6 | -48.67 | 113 | 192.8 | 192.8 | 192.8 |
| P/E ratio | -10.2 x | -8.27 x | -8.65 x | 1.74 x | -1.82 x | -2.98 x | -3.13 x | -2.64 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 18.5 x | 65 x | 59 x | 1.06 x | 16.1 x | 19.3 x | 10.3 x | 10.8 x |
| EV / Revenue | 18.5 x | 65 x | 59 x | 1.06 x | 16.1 x | 19.3 x | 10.3 x | 10.8 x |
| EV / EBITDA | -11 x | -10.9 x | -9.46 x | 1.68 x | -1.93 x | -3.57 x | -4 x | -2.9 x |
| EV / FCF | -170 x | -19.9 x | -6.26 x | 1.71 x | -1.9 x | -2.46 x | -2.73 x | -2.27 x |
| FCF Yield | -0.59% | -5.03% | -16% | 58.6% | -52.7% | -40.7% | -36.7% | -44.1% |
| Price to Book | 6.99 x | 5.64 x | 5.34 x | 0.85 x | - | 1.69 x | 2.66 x | 10.8 x |
| Nbr of stocks (in thousands) | 21,537 | 29,146 | 32,292 | 32,545 | 32,854 | 33,183 | - | - |
| Reference price 2 | 17.52 | 20.75 | 17.82 | 6.160 | 3.440 | 5.810 | 5.810 | 5.810 |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.4 | 9.3 | 9.754 | 189.6 | 7 | 10 | 18.66 | 17.79 |
| EBITDA 1 | -34.19 | -55.44 | -60.85 | 119 | -58.69 | -53.98 | -48.25 | -66.56 |
| EBIT 1 | -37.2 | -58.3 | -63.42 | 116.6 | -61.1 | -70 | -70.33 | -84.79 |
| Operating Margin | -182.35% | -626.88% | -650.17% | 61.5% | -872.86% | -700% | -376.91% | -476.63% |
| Earnings before Tax (EBT) 1 | -36.8 | -62.8 | -63.78 | 117.8 | -61.98 | -65.7 | -67.35 | -82.15 |
| Net income 1 | -36.8 | -62.8 | -63.78 | 117.8 | -61.98 | -65.7 | -61.79 | -81.01 |
| Net margin | -180.39% | -675.27% | -653.94% | 62.13% | -885.49% | -657% | -331.1% | -455.34% |
| EPS 2 | -1.720 | -2.510 | -2.060 | 3.540 | -1.890 | -1.950 | -1.857 | -2.202 |
| Free Cash Flow 1 | -2.22 | -30.43 | -91.89 | 117.4 | -59.58 | -78.4 | -70.7 | -85 |
| FCF margin | -10.88% | -327.25% | -942.03% | 61.91% | -851.14% | -784% | -378.87% | -477.79% |
| FCF Conversion (EBITDA) | - | - | - | 98.66% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 99.65% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.516 | 1.784 | 4.4 | 5.337 | 184.5 | 5.1 | 3.5 | 3.5 | 2.738 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT | -23.09 | -35.2 | -34.8 | - | - | - | - | - | - |
| Operating Margin | -307.24% | -1,973.09% | -790.91% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | -24.75 | -38.1 | -33.6 | -30.22 | 148.6 | -30.8 | -30.8 | -31.22 | - |
| Net margin | -329.27% | -2,135.65% | -763.64% | -566.2% | 80.54% | -604.02% | -880% | -891.97% | - |
| EPS | -1.140 | -1.370 | -1.130 | -0.9300 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/20 | 2/5/21 | 8/26/21 | 3/15/22 | 8/25/22 | 3/9/23 | 8/24/23 | 3/14/24 | 5/16/24 |
1CHF in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 93.8 | 174 | 133 | 249 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.22 | -30.4 | -91.9 | 117 | -59.6 | -78.4 | -70.7 | -85 |
| ROE (net income / shareholders' equity) | -49.8% | -77.9% | -59.5% | 68.8% | -30.1% | -35.3% | -46% | -129% |
| ROA (Net income/ Total Assets) | -27.9% | -42.9% | -35.4% | 54.2% | -26.9% | -31.4% | -39.7% | -97.9% |
| Assets 1 | 131.9 | 146.2 | 180.1 | 217.4 | 230.3 | 209.4 | 155.5 | 82.76 |
| Book Value Per Share 2 | 2.510 | 3.680 | 3.340 | 7.230 | - | 3.430 | 2.180 | 0.5400 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.03 | 1.45 | 0.93 | 1.18 | 0.81 | 5 | 5 | 5 |
| Capex / Sales | 5.05% | 15.6% | 9.57% | 0.62% | 11.54% | 50% | 26.79% | 28.11% |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.81
CHF
Average target price
10.35
CHF
Spread / Average Target
+78.14%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +74.42% | 214M | |
| +16.17% | 121B | |
| +17.77% | 110B | |
| +17.35% | 25.98B | |
| -24.63% | 19.27B | |
| -18.98% | 15.99B | |
| -17.69% | 15.66B | |
| -48.32% | 14.5B | |
| +57.02% | 14.47B | |
| +4.32% | 13.91B |
- Stock Market
- Equities
- MOLN Stock
- Financials Molecular Partners AG
